HEB, Hemispherx Biopharma (AMEX)NEW Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gerald Underwood who wrote (491)	10/15/1998 1:52:00 PM
From: Marty	Read Replies (1) of 857

Gerry, As I read the release, it says that HEB would have EXCLUSIVE marketing rights to CFS treatment protocols. Is that possible? No other company can offer (FDA approved) CFS treatment? That your take on it? That could be huge. I also read in the article that "Other incentives that are part of Orphan Drug designation include tax incentives for clinical research, assistance from the FDA's Office of Orphan Products Development to help coordinate research study designs, and FDA encouragement to the Company to conduct open protocols which allow patients to be added to ongoing studies." Do you know if HEB is taking advantage of any of these benefits? Thanks

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next